{"a":[{"_":"Jazz's HER2 bispecific Ziihera gains FDA approval to change practice in stomach cancer","$":{"href":"/pharma/jazz-her2-bispecific-ziihera-gains-fda-approval-change-practice-stomach-cancer","hreflang":"en"}}]}
RegulatoryapprovedZiiheraPositive
AI Analysis
Summary
Jazz Pharmaceuticals' HER2 bispecific antibody Ziihera has received FDA approval for first-line treatment of HER2-positive gastric cancer, with the company targeting peak sales exceeding $2 billion.
Financial Highlights
Guidance
$2 billion-plus peak sales target
Outcome Details
FDA approval for first-line HER2-positive stomach cancer
Importance:8/10
Sentiment:
0.85
FDA approvaloncologybispecific antibodygastric cancerHER2-positive
Related Companies
Read the original article
Published by FiercePharma on August 19, 2026 10:29 AM